SEER (SEER) Q4 2025: Installed Base Jumps 67% as Proteograph Adoption Outpaces Funding Headwinds
SEER’s fourth quarter underscored robust instrument adoption, with its installed base up 67%, but ongoing NIH funding delays and conservative customer spending muted near-term growth. The company’s strategic pivots—volume-based pricing, instrument placement programs, and product innovation—are expanding market access, yet revenue remains lumpy as the field awaits a broader shift toward unbiased proteomics. Management’s cautious outlook signals upside potential hinges on landing larger population-scale studies and unlocking further scientific validation.
Summary
- Installed Base Expansion: Proteograph placements surged, reflecting demand for deep, scalable proteomics despite budget constraints.
- Strategic Cost Discipline: Operating expenses fell sharply as SEER balanced innovation with cash preservation.
- Inflection Watch: Broader revenue acceleration depends on industry adoption tipping from pilot studies to large-scale programs.
Performance Analysis
SEER delivered 17% full-year revenue growth, with Q4 results coming in below expectations due to customer delays tied to NIH funding uncertainty. Excluding related party revenue, core business revenue advanced 33% year-over-year, highlighting underlying demand for the Proteograph platform, SEER’s flagship deep proteomics instrument suite. The installed base surged 67% to 82 instruments, a critical metric for future consumables pull-through and recurring revenue. Consumable kit volume, essential for ongoing revenue per instrument, climbed 69% as customers ramped usage for larger studies.
Gross margin held steady at 51% for the year, benefiting from higher consumable mix, while both R&D and SG&A expenses declined double digits as management sharpened cost controls. Net loss narrowed to $73.6 million, aided by lower cash burn and a 19% drop in total operating expenses. Free cash flow loss improved year-over-year, and SEER exited with $241 million in cash, providing runway to breakeven.
- Consumables Growth: Kit volumes rose sharply, signaling deeper customer engagement and potential for recurring revenue leverage.
- Operating Leverage: Expense discipline drove a 19% reduction in operating costs, improving net loss and cash flow outlook.
- Revenue Lumpiness: Delayed NIH-funded projects and small base effects kept quarterly results volatile, with large deals swinging outcomes.
While near-term growth is constrained by external funding dynamics, SEER’s expanding instrument footprint and consumables adoption position it to capture upside as market conditions stabilize and scientific validation compounds.
Executive Commentary
"We made meaningful progress across the business in 2025. Our installed base grew significantly. Consumable kit volume increased meaningfully. The proteograph was selected to power multiple population scale studies... My conviction in the transformative potential of our technology has never been stronger."
Omid Farooqsad, Chief Executive Officer and Chair of the Board
"We expect to reduce our free cash flow loss again in 2026, and we'll continue to manage our cash in an extremely prudent manner. We ended the quarter with approximately $241 million in cash, cash equivalents and investments. Importantly, we believe that with our current cash, cash equivalents and investments on hand, we have sufficient capital to reach cash flow breakeven."
David Horn, Chief Financial Officer and President
Strategic Positioning
1. Product Innovation Pipeline
SEER’s roadmap remains anchored in category-defining advances. The launch of the third-generation Proteograph 1 assay and second-generation SP200 automation instrument dramatically increased throughput, now enabling over 1,000 samples per week—nearly ten times 2021 capacity. Looking ahead, SEER is developing AI-powered analytics (Proteograph Analysis Suite 4) and a next-gen proteoform profiling assay kit for 2027, aiming to expand beyond discovery into translational research and clinical diagnostics. These moves are designed to unlock new addressable markets, especially in oncology and neurodegenerative diseases.
2. Market Access and Adoption Programs
Instrument placement strategy is broadening the user base. About 60% of 2025’s instrument installs came via the Strategic Instrument Placement (SIP) program, which leverages operating budgets rather than capital purchases to lower adoption barriers. The SEER Technology Access Center (STAC), offering sample-to-data services, further reduces friction for new users and feeds the pipeline for future direct instrument sales.
3. Scientific Validation and Community Engagement
Peer-reviewed publications nearly doubled to 70 in 2025, with high-profile studies in Nature journals and the first diagnostic test (ProView Lung by Prognomic) launched on SEER’s platform. This external validation is a leading indicator of future demand, as adoption in the research community translates into larger, recurring projects and clinical applications.
4. Commercial Execution and Partnerships
SEER’s co-marketing partnership with Thermo Fisher Scientific is gaining traction, targeting joint opportunities for population-scale studies. The ongoing search for a chief commercial officer signals an intent to professionalize and scale go-to-market execution as the installed base grows.
Key Considerations
SEER’s 2025 performance reflects a company at the intersection of scientific inflection and market inertia. The business is scaling its installed base and consumables adoption, yet broader revenue acceleration is gated by external funding and the pace of scientific community buy-in.
Key Considerations:
- Funding Sensitivity: NIH budget uncertainty and academic caution continue to delay purchasing decisions, making quarterly results volatile.
- Recurring Revenue Potential: Expansion of the installed base and consumables use sets up future operating leverage as customers scale studies.
- Activation Energy in Adoption: Transitioning users from familiar targeted proteomics to SEER’s unbiased platform takes time, but momentum is building as scientific evidence mounts.
- Share Repurchase and Capital Allocation: Management repurchased 13% of shares outstanding, reflecting confidence in long-term value and using a new $25 million buyback authorization to capitalize on price dislocation.
Risks
SEER remains highly exposed to external funding cycles, especially NIH-driven purchasing. The business faces ongoing risk from elongated sales cycles, lumpy revenue recognition, and slow activation of new users. Competitive pressure from targeted proteomics and alternative platforms may also delay the shift toward SEER’s approach. Execution risk in scaling commercial operations and translating scientific validation into large, recurring revenue streams is nontrivial.
Forward Outlook
For 2026, SEER guided to:
- Revenue of $16 million to $18 million, reflecting roughly 3% growth at the midpoint over 2025.
Full-year guidance is intentionally conservative, reflecting:
- Ongoing pressure on instrument placements and project funding amid continued NIH and macro uncertainty.
- Potential upside if additional population-scale studies are secured, which are not included in guidance.
Management expects customer caution and funding delays to persist but sees catalysts in new product launches, further scientific validation, and larger cohort wins.
Takeaways
SEER’s strategy is centered on scaling its installed base, deepening scientific validation, and broadening its product suite to capture the next wave of proteomics adoption.
- Installed Base Growth: The 67% increase in placements and strong consumables uptake are foundational for future recurring revenue, but near-term growth is lumpy due to funding headwinds.
- Disciplined Cost Management: Operating expense reductions and lower cash burn strengthen SEER’s ability to invest in innovation and weather market volatility.
- Inflection Point Watch: The shift from pilot studies to broad adoption is not yet visible, but mounting publications and clinical validation suggest the flywheel is gaining momentum—investors should monitor for signs of large-scale cohort conversions and accelerated revenue growth.
Conclusion
SEER’s 2025 results highlight strong underlying demand for deep, unbiased proteomics, with instrument and consumables growth outpacing macro headwinds. The business is well capitalized and strategically positioned, but the timing of a broader inflection in adoption remains uncertain. Investors should watch for evidence of large-scale study wins and continued scientific validation as key signals for future acceleration.
Industry Read-Through
SEER’s quarter signals broader trends in life science tools, where budget constraints and NIH funding volatility are slowing capital purchases across the sector. The shift toward high-throughput, unbiased proteomics is gaining traction, but adoption cycles remain slow as researchers weigh the transition from established targeted approaches. Competitors in mass spectrometry, automation, and data analytics should note the growing demand for scalable, AI-ready platforms and the importance of lowering adoption barriers through flexible business models. The sector’s next growth phase will likely hinge on the successful translation of scientific validation into clinical and population-scale applications.